scispace - formally typeset
Journal ArticleDOI

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Reads0
Chats0
TLDR
There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment.
Abstract
This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.

read more

Citations
More filters
Journal ArticleDOI

Interventions for the management of dry mouth: topical therapies.

TL;DR: There is no strong evidence from this review that any topical therapy is effective for relieving the symptom of dry mouth, and both integrated mouthcare systems and oral reservoir devices show promising results but there is insufficient evidence at present to recommend their use.
Journal ArticleDOI

Treatment of late sequelae after radiotherapy for head and neck cancer

TL;DR: The available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients is reviewed, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.
References
More filters

Original Article Parotid-sparing Radiotherapy: Does it Really Reduce Xerostomia?

TL;DR: In this article, the subjective degree of xerostomia in patients treated with PSRT between January 2000 and June 2003 with patients treated using conventional techniques (radiotherapy) over the same period.
Journal ArticleDOI

IMRT with the use of simultaneous integrated boost in treatment of head and neck cancer: acute toxicity evaluation.

TL;DR: The results confirm that the irradiation according to the SIB-IMRT protocol is a therapy with acceptable toxicity and there is a space for radiobiological enhancement of this regimen by concurrent chemotherapy, e.g. weekly cisplatin.
Journal ArticleDOI

3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.

TL;DR: 3D-c-IMRT using metallic compensators along with inverse calculation algorithm achieves sufficient parotid gland sparing in virtually all advanced head and neck cancers.
Related Papers (5)